Ramalin Ameliorates Alzheimer's Disease Pathology by Targeting BACE1, HDAC6, and MAPK Pathways

Abstract

Aberrant deposition of β-amyloid (Aβ) and hyperphosphorylated tau, along with neuroinflammation, are key drivers of Alzheimer's disease (AD) pathology. Here, we identify ramalin, a natural antioxidant, as a promising therapeutic agent that alleviates AD pathology by modulating β-site APP cleaving enzyme 1 (BACE1), histone deacetylase 6 (HDAC6), and the mitogen-activated protein kinases (MAPK) pathway. Ramalin reduced BACE1 protein levels, independently of its transcription, translation, or enzymatic activity, an effect mediated by inhibition of HDAC6. Consistently, HDAC6 knockout similarly decreased BACE1 levels, highlighting HDAC6 as a key regulator of BACE1. Ramalin further suppressed neuroinflammatory responses by downregulating inducible nitric oxide synthase (iNOS) and the NLR family pyrin domain containing 3 (NLRP3) inflammasome. In AD mouse models, ramalin treatment significantly attenuated neuroinflammation, Aβ plaque burden, and tau hyperphosphorylation, while improving cognitive performance. Notably, ramalin reversed Aβ oligomer-induced synaptic transmission impairment and restored synaptic vesicle recycling in hippocampal neurons. Transcriptomic analysis identified modulation of the MAPK pathway, with reduced phosphorylation of c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) implicated in tau pathology. These findings establish ramalin as a disease-modifying intervention that provides neuroprotection through concurrent regulation of BACE1, HDAC6, and MAPK signaling pathway. Collectively, our findings highlight ramalin as a compelling disease-modifying candidate with the potential to drive a breakthrough approach targeting AD pathology.

Keywords

Alzheimer's disease / BACE1 / HDAC6 / NLRP3 (NLR family pyrin domain containing 3) inflammasome / ramalin

References

[1] S. Hong, S. H. Baek, M. K. P. Lai, T. V. Arumugam, and D. G. Jo, “Aging-associated Sensory Decline and Alzheimer's Disease, ” Mol Neurodegener 19, no. 1 (2024): 93.

[2] Estimation of the Global Prevalence of Dementia in 2019 and Forecasted Prevalence in 2050: An Analysis for the Global Burden of Disease Study 2019. Lancet Public Health 2022;7(2):e105–e125.

[3] K. B. Rajan, J. Weuve, L. L. Barnes, E. A. McAninch, R. S. Wilson, and D. A. Evans, “Population Estimate of People With Clinical Alzheimer's Disease and Mild Cognitive Impairment in the United States (2020-2060),” Alzheimers Dement 17, no. 12 (2021): 1966–1975.

[4] J. Zissimopoulos, E. Crimmins, and P. St Clair, “The Value of Delaying Alzheimer's Disease Onset, ” Forum Health Econ Policy 18, no. 1 (2014):25–39.

[5] J. Wang, B. J. Gu, C. L. Masters, and Y. J. Wang, “A Systemic View of Alzheimer Disease—insights From Amyloid-beta Metabolism Beyond the Brain, ” Nature reviews Neurology 13, no. 10 (2017): 612–623.

[6] D. S. Knopman, H. Amieva, R. C. Petersen, et al., “Alzheimer Disease,” Nature reviews Disease primers 7, no. 1 (2021): 33.

[7] Y. Cho, H. G. Bae, E. Okun, T. V. Arumugam, and D. G. Jo, “Physiology and Pharmacology of Amyloid Precursor Protein, ” Pharmacology & Therapeutics 235 (2022): 108122.

[8] Y. L. Cheng, Y. Choi, C. G. Sobey, T. V. Arumugam, and D. G. Jo, “Emerging Roles of the γ-secretase-notch Axis in Inflammation, ” Pharmacology & Therapeutics 147 (2015): 80–90.

[9] D. M. Holtzman, J. C. Morris, and A. M. Goate, “Alzheimer's Disease: The Challenge of the Second Century, ” Science Translational Medicine 3, no. 77 (2011): 77sr1–77sr1.

[10] H. Hampel, S. Lista, E. Vanmechelen, et al., “β-Secretase1 Biological Markers for Alzheimer's Disease: State-of-art of Validation and Qualification, ” Alzheimers Res Ther 12, no. 1 (2020): 130.

[11] Y. Luo, B. Bolon, S. Kahn, et al., “Mice Deficient in BACE1, the Alzheimer's Beta-secretase, Have Normal Phenotype and Abolished Beta-amyloid Generation, ” Nature Neuroscience 4, no. 3 (2001): 231–232.

[12] R. Vassar, B. D. Bennett, S. Babu-Khan, et al., “Beta-secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE, ” Science 286, no. 5440 (1999): 735–741.

[13] H. N. Woo, S. H. Baik, J. S. Park, et al., “Secretases as Therapeutic Targets for Alzheimer's Disease, ” Biochemical and Biophysical Research Communications 404, no. 1 (2011): 10–15.

[14] M. Willem, A. N. Garratt, B. Novak, et al., “Control of Peripheral Nerve Myelination by the Beta-secretase BACE1, ” Science 314, no. 5799 (2006):664–666.

[15] M. H. Ou-Yang, J. E. Kurz, T. Nomura, et al., “Axonal Organization Defects in the Hippocampus of Adult Conditional BACE1 Knockout Mice,” Science Translational Medicine 10, no. 459 (2018).

[16] G. Bahn, J. S. Park, U. J. Yun, et al., “NRF2/ARE Pathway Negatively Regulates BACE1 Expression and Ameliorates Cognitive Deficits in Mouse Alzheimer's Models, ” PNAS 116, no. 25 (2019): 12516–12523.

[17] G. Bahn and D. G. Jo, “Therapeutic Approaches to Alzheimer's Disease through Modulation of NRF2, ” Neuromolecular Med 21, no. 1 (2019): 1–11.

[18] S. H. Baek, S. Hong, E. Kim, et al., “A Novel RAGE Modulator Induces Soluble RAGE to Reduce BACE1 Expression in Alzheimer's Disease, ” Adv Sci (Weinh) 12, no. 8 (2025): e2407812.

[19] G. Zuliani, M. Ranzini, G. Guerra, et al., “Plasma Cytokines Profile in Older Subjects With Late Onset Alzheimer's Disease or Vascular Dementia, ” Journal of Psychiatric Research 41, no. 8 (2007): 686–693.

[20] M. T. Heneka, M. P. Kummer, A. Stutz, et al., “NLRP3 is Activated in Alzheimer's Disease and Contributes to Pathology in APP/PS1 Mice, ” Nature 493, no. 7434 (2013): 674–678.

[21] C. K. Glass, K. Saijo, B. Winner, M. C. Marchetto, and F. H. Gage, “Mechanisms Underlying Inflammation in Neurodegeneration, ” Cell 140, no. 6 (2010): 918–934.

[22] B. Cameron and G. E. Landreth, “Inflammation, Microglia, and Alzheimer's Disease, ” Neurobiology of Disease 37, no. 3 (2010): 503–509.

[23] C. Dempsey, A. Rubio Araiz, K. J. Bryson, et al., “Inhibiting the NLRP3 Inflammasome With MCC950 Promotes Non-phlogistic Clearance of Amyloid-β and Cognitive Function in APP/PS1 Mice, ” Brain, Behavior, and Immunity 61 (2017): 306–316.

[24] S. C. McQuown, R. M. Barrett, D. P. Matheos, et al., “HDAC3 is a Critical Negative Regulator of Long-term Memory Formation, ” Journal of Neuroscience 31, no. 2 (2011): 764–774.

[25] J. S. Guan, S. J. Haggarty, E. Giacometti, et al., “HDAC2 negatively Regulates Memory Formation and Synaptic Plasticity, ” Nature 459, no. 7243 (2009): 55–60.

[26] J. S. Kim, J. H. Jun, J. Lee, et al., “HDAC6 mediates NLRP3 Inflammasome Activation in the Pathogenesis of Diabetic Retinopathy,” Metabolism 164 (2025): 156108.

[27] M. Gu, B. Ren, Y. Fang, et al., “Epigenetic Regulation in Cancer, ” MedComm 5, no. 2 (2024): e495.

[28] H. Ding, P. J. Dolan, and G. V. Johnson, “Histone Deacetylase 6 Interacts With the Microtubule-associated Protein Tau, ” Journal of Neurochemistry 106, no. 5 (2008): 2119–2130.

[29] P. Bai, P. Mondal, F. A. Bagdasarian, et al., “Development of a Potential PET Probe for HDAC6 Imaging in Alzheimer's Disease, ” Acta Pharm Sin B 12, no. 10 (2022): 3891–3904.

[30] M. Zhang, W. Wang, Q. Ye, et al., “Histone Deacetylase Inhibitors VPA and WT161 Ameliorate the Pathological Features and Cognitive Impairments of the APP/PS1 Alzheimer's disease Mouse Model by Regulating the Expression of APP Secretases, ” Alzheimers Res Ther 16, no. 1 (2024): 15.

[31] N. Govindarajan, P. Rao, S. Burkhardt, et al., “Reducing HDAC6 Ameliorates Cognitive Deficits in a Mouse Model for Alzheimer's disease,” EMBO Molecular Medicine 5, no. 1 (2013): 52–63.

[32] V. G. Magupalli, R. Negro, Y. Tian, et al., “HDAC6 mediates an Aggresome-Like Mechanism for NLRP3 and Pyrin Inflammasome Activation, ” Science 369, no. 6510 (2020).

[33] J. Bockstiegel, S. L. Wurnig, J. Engelhardt, J. Enns, F. K. Hansen, and G. Weindl, “Pharmacological Inhibition of HDAC6 Suppresses NLRP3 Inflammasome-mediated IL-1β Release, ” Biochemical Pharmacology 215 (2023): 115693.

[34] Y. Peng, J. Yu, F. Liu, et al., “Accumulation of TOX High Mobility Group Box family Member 3 Promotes the Oncogenesis and Development of Hepatocellular Carcinoma Through the MAPK Signaling Pathway, ” MedComm 5, no. 3 (2024): e510.

[35] E. K. Kim and E. J. Choi, “Pathological Roles of MAPK Signaling Pathways in human Diseases, ” Biochimica Et Biophysica Acta 1802, no. 4 (2010): 396–405.

[36] C. Ploia, X. Antoniou, A. Sclip, et al., “JNK Plays a Key Role in Tau Hyperphosphorylation in Alzheimer's disease Models, ” Journal of Alzheimer's Disease 26, no. 2 (2011): 315–329.

[37] X. Zhu, C. A. Rottkamp, H. Boux, A. Takeda, G. Perry, and M. A. Smith, “Activation of p38 Kinase Links Tau Phosphorylation, Oxidative Stress, and Cell Cycle-related Events in Alzheimer disease, ” Journal of Neuropathology and Experimental Neurology 59, no. 10 (2000): 880–888.

[38] S. Guise, D. Braguer, G. Carles, A. Delacourte, and C. Briand, “Hyperphosphorylation of Tau Is Mediated by ERK Activation During Anticancer Drug-induced Apoptosis in Neuroblastoma Cells, ” Journal of Neuroscience Research 63, no. 3 (2001): 257–267.

[39] B. Paudel, H. D. Bhattarai, H. K. Lee, H. Oh, H. W. Shin, and J. H. Yim, “Antibacterial Activities of Ramalin, Usnic Acid and Its Three Derivatives Isolated From the Antarctic Lichen Ramalina Terebrata, ” Z Naturforsch C J Biosci 65, no. 1-2 (2010): 34–38.

[40] B. Paudel, H. D. Bhattarai, H. Y. Koh, et al., “Ramalin, a Novel Nontoxic Antioxidant Compound From the Antarctic Lichen Ramalina Terebrata, ” Phytomedicine 18, no. 14 (2011): 1285–1290.

[41] S. S. Suh, T. K. Kim, J. E. Kim, et al., “Anticancer Activity of Ramalin, a Secondary Metabolite From the Antarctic Lichen Ramalina Terebrata, Against Colorectal Cancer Cells, ” Molecules (Basel, Switzerland) 22, no. 8 (2017).

[42] T. K. Kim, J. M. Hong, K. H. Kim, et al., “Potential of Ramalin and Its Derivatives for the Treatment of Alzheimer's Disease, ” Molecules (Basel, Switzerland) 26, no. 21 (2021).

[43] D. G. Jo, T. V. Arumugam, H. N. Woo, et al., “Evidence That Gamma-secretase Mediates Oxidative Stress-induced Beta-secretase Expression in Alzheimer's Disease, ” Neurobiology of Aging 31, no. 6 (2010): 917–925.

[44] A. R. Gwon, J. S. Park, T. V. Arumugam, et al., “Oxidative Lipid Modification of Nicastrin Enhances Amyloidogenic γ-secretase Activity in Alzheimer's Disease, ” Aging Cell 11, no. 4 (2012): 559–568.

[45] T. Gilon, O. Chomsky, and R. G. Kulka, “Degradation Signals for Ubiquitin System Proteolysis in Saccharomyces Cerevisiae, ” Embo Journal 17, no. 10 (1998): 2759–2766.

[46] D. M. Kim, H. Kim, J. H. Yeon, J. H. Lee, and H. O. Park, “Identification of a Mitochondrial DNA Polymerase Affecting Cardiotoxicity of Sunitinib Using a Genome-Wide Screening on S. pombe Deletion Library, ” Toxicological Sciences 149, no. 1 (2016): 4–14.

[47] D. U. Kim, J. Hayles, D. Kim, et al., “Analysis of a Genome-wide Set of Gene Deletions in the Fission Yeast Schizosaccharomyces Pombe, ” Nature Biotechnology 28, no. 6 (2010): 617–623.

[48] M. T. Heneka, M. P. Kummer, and E. Latz, “Innate Immune Activation in Neurodegenerative Disease, ” Nature Reviews Immunology 14, no. 7 (2014): 463–477.

[49] S. W. Robinson, J. M. Bourgognon, J. G. Spiers, et al., “Nitric Oxide-mediated Posttranslational Modifications Control Neurotransmitter Release by Modulating Complexin Farnesylation and Enhancing Its Clamping Ability, ” Plos Biology 16, no. 4 (2018): e2003611.

[50] Y. Li, H. Wang, Y. Wang, et al., “Alterations in the Axon Initial Segment Plasticity Is Involved in Early Pathogenesis in Alzheimer's Disease, ” MedComm 5, no. 11 (2024): e768.

[51] S. H. Kim and T. A. Ryan, “CDK5 serves as a Major Control Point in Neurotransmitter Release, ” Neuron 67, no. 5 (2010): 797–809.

[52] W. Huang da, B. T. Sherman, and R. A. Lempicki, “Systematic and Integrative Analysis of Large Gene Lists Using DAVID Bioinformatics Resources, ” Nature Protocols 4, no. 1 (2009): 44–57.

[53] B. T. Sherman, M. Hao, J. Qiu, et al., “DAVID: A Web Server for Functional Enrichment Analysis and Functional Annotation of Gene Lists (2021 update), ” Nucleic Acids Res 50, no. W1 (2022): W216–W221.

[54] M. Kanehisa and S. Goto, “KEGG: Kyoto encyclopedia of Genes and Genomes, ” Nucleic Acids Res 28, no. 1 (2000): 27–30.

[55] L. B. Yang, K. Lindholm, R. Yan, et al., “Elevated Beta-secretase Expression and Enzymatic Activity Detected in Sporadic Alzheimer Disease, ” Nature Medicine 9, no. 1 (2003): 3–4.

[56] J. Han, J. H. Sul, J. Lee, et al., “Engineered Exosomes With a Photoinducible Protein Delivery System Enable CRISPR-Cas-based Epigenome Editing in Alzheimer's Disease, ” Science Translational Medicine 16, no. 759 (2024): eadi4830.

[57] P. Wang, Z. Wang, and J. Liu, “Role of HDACs in Normal and Malignant Hematopoiesis, ” Molecular cancer 19, no. 1 (2020): 5.

[58] J. H. Jun, J. S. Kim, L. F. Palomera, and D. G. Jo, “Dysregulation of Histone Deacetylases in Ocular Diseases, ” Arch Pharm Res 47, no. 1 (2024): 20–39.

[59] J. Park, H.-J. Ha, E. S. Chung, et al., “O-GlcNAcylation Ameliorates the Pathological Manifestations of Alzheimer's Disease by Inhibiting Necroptosis, ” Science Advances 7, no. 3 (2021): eabd3207.

[60] J. S. Kim, Y. Cho, J. Lee, et al., “N(5)-((perfluorophenyl)amino)Glutamine Regulates BACE1, Tau Phosphorylation, Synaptic Function, and Neuroinflammation in Alzheimer's disease Models, ” Biosci Trends 19, no. 1 (2025): 102–115.

[61] S. H. Baek, S. J. Park, J. I. Jeong, et al., “Inhibition of Drp1 Ameliorates Synaptic Depression, Aβ Deposition, and Cognitive Impairment in an Alzheimer's Disease Model, ” Journal of Neuroscience 37, no. 20 (2017):5099–5110.

[62] S. Sarkar, E. Malovic, B. Plante, et al., “Rapid and Refined CD11b Magnetic Isolation of Primary Microglia With Enhanced Purity and Versatility, ” Journal of visualized experiments: JoVE no. 122 (2017).

[63] J. R. Bae, W. Lee, Y. O. Jo, et al., “Distinct Synaptic Vesicle Recycling in Inhibitory Nerve Terminals Is Coordinated by SV2A, ” Progress in Neurobiology 194 (2020): 101879.

[64] Y. Lee, S. Han, J. Lee, et al., “A Novel Multi-target Compound Mitigates Amyloid Plaques, Synaptic Deficits, and Neuroinflammation in Alzheimer's disease Models, ” Arch Pharm Res 48, no. 7-8 (2025): 745–764.

[65] T. K. Kim, Y. Cho, J. Kim, et al., “Synthesis and Evaluation of Chloride-Substituted Ramalin Derivatives for Alzheimer's Disease Treatment, ” Molecules (Basel, Switzerland) 29, no. 15 (2024).

[66] T. K. Kim, J. M. Hong, Y. Cho, et al., “Synthesis and Biological Evaluation of Novel Ramalin Derivatives as Multi-Target Agents for Alzheimer's Disease, ” Molecules (Basel, Switzerland) 30, no. 9 (2025).

[67] Y. Cho, J. Lee, J. S. Kim, et al., “RA-PR058, a Novel Ramalin Derivative, Reduces BACE1 Expression and Phosphorylation of Tau in Alzheimer's disease Mouse Models, ” Anim Cells Syst (Seoul) 29, no. 1 (2025): 122–134.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.